Hospital
Tri-City Hospital
Tri-City Hospital was paid $44.74M by Medicaid between Jan 2018 and Dec 2024, across 267 billing codes. Its largest line is 0450, Emergency room services — 27% of everything it billed.
33Billing provider infoTRI-CITY HOSPITAL
OCEANSIDE, CA 92056
OCEANSIDE, CA 92056
33aNPI1801861190assigned 02/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.74M
24GClaims824,334
24DCodes billed267
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#72 of 410
Median peer was paid$6.90M
This provider vs. median6.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 164,780 | $8.60M | |
| 2019 | 149,448 | $7.07M | |
| 2020 | 98,346 | $5.32M | |
| 2021 | 97,265 | $5.79M | |
| 2022 | 108,966 | $6.30M | |
| 2023 | 111,526 | $6.34M | |
| 2024incomplete | 94,003 | $5.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 27% | 50,237 | 44,668 | $12.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.2% | 25,298 | 23,384 | $3.66M |
| 99499 | 6.0% | 12,943 | 11,580 | $2.67M | |
| 80053 | Comprehensive metabolic panel | 5.3% | 56,530 | 49,637 | $2.35M |
| 81003 | 2.3% | 16,960 | 16,117 | $1.02M | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 9,195 | 8,463 | $962K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 9,671 | 8,139 | $940K |
| J3490 | Unclassified drugs | 2.1% | 26,661 | 19,836 | $925K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 7,564 | 7,115 | $914K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 4,975 | 4,772 | $824K |
| 86769 | 1.8% | 9,191 | 8,943 | $784K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 34,130 | 30,421 | $704K |
255 more codes
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.5% | 5,414 | $678K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 15,127 | $619K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 5,464 | $572K |
| 99284 | Emergency room visit (serious) | 1.2% | 3,391 | $531K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 8,400 | $523K |
| 99285 | Emergency room visit (most serious) | <1% | 2,310 | $438K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,717 | $399K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,176 | $373K |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | <1% | 2,233 | $345K |
| 81025 | <1% | 8,831 | $339K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,161 | $339K |
| 99199 | Unlisted special service, procedure or report | <1% | 5,273 | $330K |
| 84484 | <1% | 23,230 | $327K | |
| 76801 | <1% | 3,426 | $311K | |
| 0710 | <1% | 1,389 | $292K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,069 | $291K |
| 83880 | <1% | 5,275 | $283K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,065 | $277K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,703 | $273K |
| Z7502 | <1% | 6,758 | $260K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,855 | $256K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 554 | $247K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 935 | $225K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,481 | $204K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,425 | $203K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,728 | $192K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,916 | $190K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,511 | $189K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,498 | $182K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,293 | $180K |
| 86900 | <1% | 4,196 | $177K | |
| 73564 | <1% | 1,986 | $176K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,732 | $175K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,832 | $171K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,328 | $170K |
| 0761 | <1% | 2,770 | $158K | |
| 93970 | <1% | 1,280 | $156K | |
| 73610 | <1% | 1,755 | $151K | |
| 93971 | <1% | 1,994 | $148K | |
| 76642 | <1% | 1,329 | $143K | |
| 73030 | <1% | 1,911 | $137K | |
| 73630 | <1% | 2,190 | $135K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,546 | $116K |
| 70498 | <1% | 856 | $115K | |
| 0270 | <1% | 3,798 | $114K | |
| 76813 | <1% | 878 | $111K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 928 | $110K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,783 | $105K |
| 82553 | <1% | 12,735 | $102K | |
| 83690 | <1% | 18,937 | $99K | |
| 0250 | <1% | 7,033 | $96K | |
| 81001 | <1% | 19,143 | $95K | |
| 82948 | <1% | 7,192 | $89K | |
| 73130 | <1% | 1,289 | $87K | |
| 84702 | <1% | 4,637 | $85K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,551 | $85K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,563 | $84K |
| 70496 | <1% | 759 | $83K | |
| 93017 | <1% | 689 | $83K | |
| 97162 | <1% | 1,009 | $82K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,786 | $82K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,762 | $79K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 348 | $77K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,573 | $71K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 136 | $67K |
| Z9725 | <1% | 1,558 | $67K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,093 | $64K |
| 70486 | <1% | 400 | $63K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,139 | $63K |
| 73110 | <1% | 802 | $61K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,947 | $59K |
| J1815 | Injection, insulin, per 5 units | <1% | 835 | $59K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,538 | $59K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,776 | $58K |
| 90715 | <1% | 1,909 | $57K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,560 | $57K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 547 | $56K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,388 | $55K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,788 | $54K |
| 72110 | <1% | 607 | $50K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 640 | $49K |
| 83605 | <1% | 5,983 | $48K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 610 | $48K |
| 81015 | <1% | 2,913 | $48K | |
| 87040 | <1% | 3,754 | $48K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,467 | $47K |
| 82550 | <1% | 10,411 | $46K | |
| 0762 | <1% | 791 | $46K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,116 | $45K |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | <1% | 283 | $45K |
| 59025 | Fetal non-stress test | <1% | 563 | $45K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,255 | $44K |
| 77066 | Tomosynthesis, mammo | <1% | 535 | $42K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 202 | $42K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,364 | $39K |
| 97014 | <1% | 1,562 | $38K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,822 | $38K |
| 85027 | <1% | 7,911 | $38K | |
| 84703 | <1% | 4,960 | $37K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 981 | $37K |
| 0272 | <1% | 1,792 | $36K | |
| 85610 | <1% | 9,725 | $36K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,495 | $36K |
| 29125 | <1% | 125 | $34K | |
| 73590 | <1% | 903 | $33K | |
| 97161 | <1% | 335 | $32K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 944 | $31K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 185 | $30K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 213 | $29K |
| 87503 | <1% | 2,777 | $28K | |
| 73502 | <1% | 642 | $26K | |
| 73140 | <1% | 250 | $26K | |
| 83735 | <1% | 6,326 | $25K | |
| 73080 | <1% | 388 | $25K | |
| 87186 | <1% | 3,593 | $24K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $24K |
| 86140 | <1% | 4,294 | $24K | |
| 72100 | <1% | 357 | $22K | |
| A9505 | Thallium tl-201 thallous chloride, diagnostic, per millicurie | <1% | 327 | $22K |
| 72131 | <1% | 214 | $22K | |
| 85379 | <1% | 1,835 | $20K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 338 | $20K |
| 83520 | <1% | 2,609 | $20K | |
| 96367 | <1% | 451 | $19K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,540 | $19K |
| 86901 | <1% | 4,192 | $18K | |
| 82805 | <1% | 280 | $18K | |
| 87070 | <1% | 1,129 | $17K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,275 | $17K |
| 85730 | <1% | 4,343 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 907 | $15K |
| 76770 | <1% | 249 | $15K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 140 | $15K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,772 | $14K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 378 | $14K |
| 86850 | <1% | 1,769 | $14K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 545 | $14K |
| 85007 | <1% | 3,444 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,014 | $13K |
| 97172 | <1% | 319 | $13K | |
| 73090 | <1% | 334 | $13K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,560 | $12K |
| 80061 | Lipid panel | <1% | 1,033 | $12K |
| 87077 | <1% | 1,940 | $12K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,150 | $12K |
| 80306 | <1% | 1,779 | $12K | |
| A9270 | Non-covered item or service | <1% | 5,750 | $11K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 93 | $11K |
| 85651 | <1% | 3,344 | $10K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 388 | $10K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 306 | $10K |
| 96376 | <1% | 1,871 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 247 | $9K |
| 97113 | <1% | 183 | $9K | |
| 77065 | Tomosynthesis, mammo | <1% | 125 | $9K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,718 | $9K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 102 | $8K |
| 86756 | <1% | 562 | $8K | |
| 97139 | <1% | 245 | $7K | |
| 84100 | <1% | 2,571 | $7K | |
| 87210 | <1% | 520 | $7K | |
| 87147 | <1% | 528 | $7K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 173 | $7K |
| 72050 | <1% | 72 | $6K | |
| 71250 | <1% | 42 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 178 | $6K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,206 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,290 | $6K |
| 29515 | <1% | 37 | $6K | |
| 0320 | <1% | 68 | $5K | |
| 94644 | <1% | 185 | $5K | |
| C1769 | Guide wire | <1% | 71 | $5K |
| 12001 | <1% | 39 | $5K | |
| 12011 | <1% | 14 | $5K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 14 | $5K |
| 82375 | <1% | 691 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 92 | $4K |
| 99070 | <1% | 310 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 158 | $3K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 116 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 130 | $3K |
| 82330 | <1% | 339 | $3K | |
| 71020 | <1% | 178 | $3K | |
| 76870 | <1% | 54 | $3K | |
| 82962 | <1% | 217 | $3K | |
| 73562 | <1% | 51 | $3K | |
| 74019 | <1% | 56 | $3K | |
| 73552 | <1% | 82 | $3K | |
| 84145 | <1% | 15 | $3K | |
| 0510 | <1% | 35 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 17 | $2K |
| 71010 | <1% | 49 | $2K | |
| 0001A | <1% | 93 | $2K | |
| 82140 | <1% | 346 | $2K | |
| 74018 | <1% | 47 | $2K | |
| 94760 | <1% | 182 | $2K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 172 | $2K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 197 | $2K |
| 97116 | <1% | 95 | $2K | |
| 72128 | <1% | 25 | $2K | |
| 0002A | <1% | 81 | $2K | |
| 86308 | <1% | 50 | $2K | |
| 83050 | <1% | 477 | $2K | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 50 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 183 | $1K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 493 | $1K |
| 87420 | <1% | 165 | $1K | |
| 74241 | <1% | 15 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 298 | $1K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 64 | $1K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 21 | $1K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 597 | $1K |
| Z7610 | <1% | 82 | $1K | |
| 97802 | <1% | 13 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 54 | $1K |
| 71111 | <1% | 12 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 155 | $974.89 |
| 97750 | <1% | 28 | $912.18 | |
| 73620 | <1% | 12 | $848.94 | |
| 76536 | <1% | 12 | $836.71 | |
| Z7500 | <1% | 19 | $647.90 | |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 14 | $630.00 |
| 87205 | <1% | 85 | $614.20 | |
| 87641 | <1% | 121 | $567.34 | |
| 74022 | <1% | 13 | $511.27 | |
| 77080 | <1% | 13 | $511.19 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 63 | $501.60 |
| 82728 | <1% | 70 | $440.93 | |
| 82150 | <1% | 95 | $427.65 | |
| 82803 | <1% | 55 | $404.21 | |
| 82010 | <1% | 46 | $346.88 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 87 | $339.05 |
| 84439 | <1% | 43 | $323.26 | |
| 71101 | <1% | 12 | $319.68 | |
| 87071 | <1% | 50 | $309.57 | |
| 83615 | <1% | 70 | $304.61 | |
| 0370 | <1% | 652 | $289.37 | |
| 84550 | <1% | 30 | $258.61 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $209.54 |
| 80051 | <1% | 135 | $207.37 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 12 | $204.51 |
| 85018 | <1% | 124 | $185.45 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 27 | $166.94 |
| 86317 | <1% | 12 | $151.65 | |
| 85014 | <1% | 142 | $120.51 | |
| 84480 | <1% | 15 | $116.61 | |
| 86780 | <1% | 12 | $115.18 | |
| 84436 | <1% | 13 | $64.96 | |
| 82607 | <1% | 13 | $59.60 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 12 | $29.85 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 58 | $0.01 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 60 | $0.01 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 2,031 | $0.00 |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 120 | $0.00 |
| 91300 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRIVAS, RAY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Tri City Hospital | Oceanside, CA | $838K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.